Healthy middle-aged Britons to be offered Alzheimer’s drug in trial aiming to prevent dementia
A trial launching in Britain will give a drug currently used to treat Alzheimer's to healthy middle-aged and older people, testing whether it can prevent the disease before symptoms ever emerge. Screening for the first European participants begins on Monday, with more than 15 UK centres expected to take part in the global study, which researchers describe as a fundamental shift from treating dementia after diagnosis to trying to stop it developing in the first place. Should it succeed, the approach could eventually see high-risk individuals prescribed preventive treatment in mid-life, a strategy some have likened to "statins for the brain".
Around 1,600 healthy adults aged 55 to 80 will be recruited worldwide for the PrevenTron trial, which will run for four to six years and is led in the UK by Surrey and Borders Partnership NHS Foundation Trust. Participants will undergo memory tests and a blood test for the protein p-tau217, an early biological marker of Alzheimer's, before being randomly assigned the drug, trontinemab, or a placebo. Developed by Roche, trontinemab is designed to clear amyloid plaques from the brain faster than existing treatments lecanemab and donanemab, both of which are licensed in Britain but not funded on the NHS on cost-effectiveness grounds.
In short
- UK trial to test if an Alzheimer's drug can prevent dementia
- 1,600 healthy over-55s to get trontinemab or placebo for years
- Success could lead to preventive "statins for the brain" approach
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Testing trontinemab before symptoms appear could reveal whether clearing amyloid early prevents or delays Alzheimer’s, potentially preserving years of health and independence. A carefully monitored trial with a placebo group can provide evidence about benefits and risks before preventive treatment is considered for people at higher risk.
The case against
Giving a potent Alzheimer’s drug to healthy people raises a higher bar for safety: participants may feel well for years, while treatment could cause harm or offer no meaningful protection. The trial’s long duration and early biological marker also leave uncertainty about whether changes in p-tau217 or amyloid translate into less dementia, and whether any eventual preventive use would be affordable and fair.
Explained simply
Alzheimer’s disease is the most common cause of dementia, a group of conditions that affect memory and thinking. Changes linked to Alzheimer’s can begin in the brain years before symptoms appear. Amyloid plaques are one such change, and some existing treatments aim to remove them.
Trontinemab, developed by the pharmaceutical company Roche, is a drug designed to clear amyloid plaques. The PrevenTron study is testing whether giving it to people without memory problems can delay or prevent Alzheimer’s, particularly among those whose blood test suggests early disease-related changes. Participants will also have memory tests and receive either the drug or a placebo.
The study is led in Britain by Surrey and Borders Partnership NHS Foundation Trust and is part of a wider international effort. Its results could help researchers understand whether treatment before symptoms is useful, and who might benefit.
Art Culture Europe Health Medicine Research Science UK World